To explore the clinical value of AI-assisted pulmonary rehabilitation education in patients undergoing thoracoscopic surgery for lung cancer. This was a non-randomized, two-period comparative study comparing AI-assisted education with routine education for postoperative pulmonary rehabilitation in lung cancer patients. Patients who underwent thoracoscopic radical lung cancer surgery in a Chinese general hospital between January and December 2024 were selected. Based on the type of education received, patients were divided into the routine education group and the AI-assisted education group. Relevant information was collected through electronic medical records. A total of 128 cases were included, with 65 in the routine group and 63 in the AI-assisted group. Baseline data showed no significant intergroup differences. Compared with routine education, AI-assisted education significantly improved patient adherence to exercise training (51.6 ± 7.5 vs. 43.1 ± 6.4, P < 0.001) and postoperative self-efficacy (91.3 ± 6.7 vs. 77.2 ± 7.0, P < 0.001). The incidence of complications was lower in the AI-assisted group (4.8

This research aimed to explore the significance of tumor volume change rate (TVCR) in predicting pathological response and survival prognosis for esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy. Esophageal squamous cell carcinoma patients receiving neoadjuvant immunochemotherapy followed by esophagectomy between October 2020 and March 2024 were reviewed. The TVCR was measured and calculated through three-dimensional reconstruction based on computed tomography images. Pathological response, operative characteristics, postoperative complications were compared between the group with TVCR ≤ 45

Soft-tissue sarcomas present a significant clinical challenge owing to their high postoperative recurrence rates and poor responsiveness to radiotherapy and chemotherapy. The insufficient infiltration of immune cells into the tumor microenvironment further limits the efficacy of immunotherapy. Photodynamic therapy (PDT) can induce immunogenic cell death (ICD) in tumor cells by releasing tumor-associated antigens. These antigens can be used to activate dendritic cells (DCs) in vitro and extract DC vesicles. These vesicles can activate T cells in a more effective and specific manner, promoting their maturation and tumor infiltration, thereby achieving effective tumor immunotherapy. After delivering photosensitizers to the tumor site via nanocarriers, the tumor antigens generated in situ by PDT can further enhance tumor accumulation and the anti-tumor immune response of these T cells. Based on this rationale, we developed a cell membrane-based nanoplatform that integrates PDT and T cell activation. Nanoparticles were fabricated by coating indocyanine green-loaded mesoporous polydopamine nanoparticles with a hybrid membrane derived from DCs activated by PDT-released antigens and tumor cells (DTM-MI). In vitro, DTM-MI demonstrated efficient tumor cell targeting and laser irradiation, produced abundant reactive oxygen species (ROS), and induced tumor cell death and release of ICD-related molecules. DTM-MI selectively accumulated in tumors of tumor-bearing mice in vivo Combined with PD-L1 antibody and laser irradiation, DTM-MI significantly inhibited tumor growth while elevating serum levels of immune-related cytokines, confirming anti-tumor immune activation. Lymph nodes showed increased T-cell and CD8 + T-cell populations, and tumor sites exhibited enhanced CD8 + T-cell and cytotoxic T lymphocyte (CTL) infiltration. The dual targeting of tumor cells and T cells by DTM-MI coupled with DC membrane-mediated T-cell activation and homing to PDT-treated regions facilitated potent tumor killing. Laser-triggered immunogenic cell death and antigen release further amplify T cell-mediated anti-tumor immunity, presenting a promising therapeutic approach for sarcomas.

The optimal time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery for esophageal squamous cell carcinoma remains unknown. This research aims to assess the impact of time interval on pathological response and survival prognosis. Esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy between January 2021 and March 2024 were included. The pathological response, survival outcomes, surgical outcomes, and postoperative complications were compared between the timely surgery group (time interval ≤ 6 weeks) and the delayed surgery group (time interval > 6 weeks). A total of 133 cases were included in this research. The pathological complete response (pCR) rates in timely surgery group and delayed surgery group were 23.4

OBJECTIVE:This retrospective study aimed to evaluate whether long-term metformin use is associated with less aggressive clinicopathological characteristics in patients with invasive lung adenocarcinoma (LUAD) and type 2 diabetes mellitus (T2DM). METHODS:We reviewed patients with both invasive LUAD and T2DM who underwent curative lung cancer resection and lymph node dissection between January 2012 and August 2022. Patients were divided into a metformin group and a non-metformin group based on their antidiabetic treatment. Clinicopathological outcomes included tumor size, TNM stage, histologic differentiation, Ki-67 expression, and pathological subtypes. Comparisons were made using Student's t-test, Mann-Whitney U test, χ² test, or Fisher's exact test, as appropriate. RESULTS:A total of 130 patients were included (45 metformin users and 85 non-users), with no significant differences in baseline characteristics. The metformin group showed smaller tumors (1.78 ± 0.87 cm vs. 2.21 ± 1.28 cm; p = 0.049), fewer cases of high Ki-67 expression (>15%) (35.6% vs. 62.3%; p = 0.004), and no lymph node metastasis (0% vs. 15.3%; p = 0.022). Additionally, patients on metformin had better differentiation (p = 0.039) and earlier TNM stages (p = 0.03). CONCLUSION:Long-term metformin use in diabetic patients with invasive LUAD was associated with more favorable clinicopathological features, including smaller tumor size, lower proliferative index, and absence of nodal metastasis. These findings support a potential anti-tumor role of metformin in lung adenocarcinoma.

This research aimed to compare the efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma. Patients with esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy plus albumin-bound paclitaxel and platinum-based chemotherapy followed by esophagectomy from December 2020 to May 2024 were retrospectively analyzed. The therapeutic efficacy, adverse reactions, and postoperative complications between the two- and three-cycle groups were analyzed using chi-square test and independent sample t-test. The overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method with log-rank test. A total of 138 esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy plus chemotherapy were enrolled. The R0 resection rates were 94.5

BACKGROUND:Camrelizumab (an anti-programmed cell death protein-1 antibody) combined with apatinib (an antiangiogenic agent) has conferred benefits for advanced NSCLC. This study aimed to assess the efficacy and safety of camrelizumab and apatinib alongside chemotherapy in patients with resectable stage IIIA (N2) NSCLC as neoadjuvant therapy. METHODS:Patients with stage IIIA (N2) NSCLC were treated with a combination of chemotherapy, camrelizumab (200 mg, once every 3 weeks [q3w]), and apatinib (250 mg, once daily). Surgery was planned after 2-4 cycles of therapy. The primary endpoint was major pathological response (MPR) rate, with secondary endpoints including pathological complete response (pCR) rate, R0 resection rate, objective response rate (ORR), and safety. The trial was registered at ChiCTR.org.cn (ChiCTR2200059608). RESULTS:Thirty-one patients were enrolled from August 4, 2021, to October 8, 2023. The disease control rate (DCR) was 93.5%, while the ORR was 87.1% and a clinical down-staging rate of 19.4%. Among them, 20 patients underwent complete resection, the MPR rate was 65.0%, and the pCR rate was 40%. Any grade neoadjuvant adverse events (AEs) were reported in 31 (100%) of the patients, and grade 3/4 AEs in 19 (61.3%). The most common AEs of any grade were fatigue (61.3%), nausea (54.8%), and decreased white blood cell count (51.6%). These conditions typically return to normal within a short period following observation or pharmacological treatment. No treatment-related deaths occurred. CONCLUSIONS:The synergistic application of chemotherapy with camrelizumab and apatinib showed clinically meaningful anti-tumor activity and manageable safety, with few hematologic toxicities, and might be a promising therapeutic alternative for individuals with resectable stage IIIA (N2) NSCLC.

Phosphatidylinositol 3-kinase (PI3K) is frequently hyperactivated in cancer, playing pivotal roles in the pathophysiology of both malignant and immune cells. The impact of PI3K inhibitors on the tumor microenvironment (TME) within lung cancer remains largely unknown. In this study, we explored the regulatory effects of GNE-493, an innovative dual inhibitor of PI3K and mammalian target of rapamycin (mTOR), on the TME of lung cancer. First, through the analysis of The Cancer Genome Atlas-lung squamous cell carcinoma (LUSC) cohort, we found PIK3CA to be related to CD8 T cells, which may affect the overall survival rate of patients by affecting CD8 function. We herein demonstrated that GNE-493 can significantly inhibit tumor cell proliferation and promote cell apoptosis while increasing the expression of the immunogenic death-related molecules CRT and HSP70 using in vitro cell proliferation and apoptosis experiments on the murine KP lung cancer cell line and human A549 lung cancer cell line. Next, through the establishment of an orthotopic tumor model in vivo, it was found that after GNE-493 intervention, the infiltration of CD4+ and CD8+ T cells in mouse lung tumor was significantly increased, and the expression of CRT in tumors could be induced to increase. To explore the mechanisms underlying PI3K inhibition-induced changes in the TME, the gene expression differences of T cells in the control group versus GNE-493-treated KP tumors were analyzed by RNA-seq, and the main effector pathway of anti -tumor immunity was identified. The IFN/TNF family molecules were significantly upregulated after GNE-493 treatment. In summary, our findings indicate that GNE-493 promotes immunogenic cell death in lung cancer cells, and elucidates its regulatory impact on molecules associated with the adaptive immune response. Our study provides novel insights into how PI3K/mTOR inhibitors exert their activity by modulating the tumor-immune interaction.

This research aimed to clarify the metastatic patterns of subcarinal, right and left recurrent laryngeal nerve lymph nodes in thoracic esophageal squamous cell carcinoma and to investigate appropriate strategies for lymph node dissection. Patients with thoracic esophageal squamous cell carcinoma receiving esophagectomy from December 2020 to April 2024 were retrospectively analyzed. Risk factors for subcarinal, right and left recurrent laryngeal nerve lymph nodes metastasis were determined by chi-square test and multivariate logistic regression analysis. We visualized the metastasis rates of these specific lymph nodes based on the different clinicopathological characteristics. Correlation between subcarinal, right and left recurrent laryngeal lymph nodes metastasis and postoperative complications were also analyzed. A total of 503 thoracic esophageal squamous carcinoma patients who underwent esophagectomy were enrolled. The metastasis rates of subcarinal, right and left recurrent laryngeal nerve lymph nodes were 10.3

Forkhead box protein 1 (FOXP1) serves as a tumour promoter or suppressor depending on different cancers, but its effect in oesophageal squamous cell carcinoma has not been fully elucidated. This study investigated the role of FOXP1 in oesophageal squamous cell carcinoma through bioinformatics analysis and experimental verification. We determined through public databases that FOXP1 expresses low in oesophageal squamous cell carcinoma compared with normal tissues, while high expression of FOXP1 indicates a better prognosis. We identified potential target genes regulated by FOXP1, and explored the potential biological processes and signalling pathways involved in FOXP1 in oesophageal squamous cell carcinoma through GO and KEGG enrichment, gene co-expression analysis, and protein interaction network construction. We also analysed the correlation between FOXP1 and tumour immune infiltration levels. We further validated the inhibitory effect of FOXP1 on the proliferation of oesophageal squamous cell carcinoma cells through CCK-8, colony formation and subcutaneous tumour formation assays. This study revealed the anticarcinogenic effect of FOXP1 in oesophageal squamous cell carcinoma, which may serve as a novel biological target for the treatment of tumour.

目的 探讨混合磨玻璃结节的CT征象对肺腺癌病理亚型及分化程度的预测价值.方法 回顾性分析2021年5月-12月厦门大学附属第一医院胸外二科术后病理为浸润性腺癌(invasive adenocarcinoma,IAC)的混合磨玻璃结节66例患者的临床资料,其中男20例、女46例,年龄35～75岁.术前分析其CT表现,术后切开病灶剖面,区分其磨玻璃成分与实性成分并得出不同位置的病理结果,按术后病理结果将患者分为低危组(贴壁型为主且没有微乳头亚型和实体亚型成分)16例,中危组(乳头或腺泡型为主且没有微乳头亚型和实体亚型成分)38例,高危组(含有微乳头或实体亚型)12例,分析比较三组患者CT特征与病理亚型及分化程度的关系.结果 在66例IAC患者中,实性成分的浸润程度均大于磨玻璃成分,当实性成分比(consolidation tumor ratio,CTR)≥25％(敏感度为90.2％,特异度为64.0％,P=0.005),平均CT值＞-283.95 HU(敏感度为82.9％,特异度为64.0％,P=0.000)时组织学分级更倾向于中、低分化.具有中、高危组亚型的IAC,其CTR、Ki-67、平均CT值及组织学分级都高于低危组结节.结论 IAC混合磨玻璃结节中实性成分浸润程度高于磨玻璃成分,可根据其CT特征预测肺腺癌病理亚型、Ki-67表达程度及组织学分级,对于确定手术时机有重要的临床意义.

MicroRNA是一类非编码且在进化上高度保守的小分子RNA,通过与信使RNA(mRNA)的特异性结合,从而调控基因的表达.目前,关于microRNA的研究已引起全世界的高度重视,其中miR-139-5p表达在癌症的变化发展过程中起着重要作用.在相当一部分癌症中,如肺癌、食管癌、乳腺癌、口腔舌鳞状细胞癌、肝癌,具有抑制癌细胞增殖、转移、侵袭的作用.在癌症治疗中,miR-139-5p可联合部分抗癌药物,延缓抗癌药物的耐药性,以及增强肿瘤对放疗的敏感性,对癌症预后有积极的影响;且其在其它疾病的组织、细胞研究领域中分别起着不同作用,如神经细胞、炎症组织.本文对miR-139-5p的研究现状展开分析.

Polo-like kinase 1 (PLK1) is a key regulator of cell division, and its abnormal expression is related to the progression and prognosis of cancers. However, the effect of PLK1 inhibitor onvansertib on the growth of lung adenocarcinoma (LUAD) has not been explored. In this study, we performed a series of bioinformatics and experimental analyses to comprehensively investigate the role of PLK1 in LUAD. We used CCK-8 assay and colony formation assay to evaluate the growth inhibitory ability of onvansertib. Furthermore, flow cytometry was applied to exploit the effects of onvansertib on cell cycle, apoptosis, and mitochondrial membrane potential. Moreover, the therapeutic potential of onvansertib was assessed in vivo by using xenograft tumor and patient-derived xenograft (PDX) models. We found that onvansertib significantly induced the apoptosis and inhibited the proliferation and migration of LUAD cells. Mechanistically, onvansertib arrested the cells at G2/M phase and enhanced the levels of reactive oxidative species in LUAD. Accordingly, onvansertib regulated the expression of glycolysis-related genes and improved the cisplatin resistance in LUAD. Notably, the protein levels of β-catenin and c-Myc were affected by onvansertib. Taken together, our findings provide insight into the function of onvansertib and shed light on the potential clinical application of onvansertib for the treatment of patients with LUAD.

BACKGROUND:The utility of circulating tumor DNA to monitor molecular residual disease (MRD) has been clinically confirmed to predict disease recurrence in non-small cell lung cancer (NSCLC) patients after radical resection. Patients with longitudinal undetectable MRD show a favorable prognosis and might not benefit from adjuvant therapy. PATIENTS AND METHODS:The CTONG 2201 trial is a prospective, multicenter, single-arm study (ClinicalTrials.gov identifier, NCT05457049), designed to evaluate the hypothesis that no adjuvant therapy is needed for patients with longitudinal undetectable MRD. Pathologically confirmed stage IB-IIIA NSCLC patients who have undergone radical resection will be screened. Only patients with 2 consecutive rounds of undetectable MRD will be enrolled (first at days 3-10, second at days 30 ± 7 after surgery), and admitted for imaging and MRD monitoring every 3 months without adjuvant therapy. The primary endpoint is the 2-year disease-free survival rate for those with longitudinal undetectable MRD. The recruitment phase began in August 2022 and 180 patients will be enrolled. CONCLUSIONS:This prospective trial will contribute data to confirm the negative predictive value of MRD on adjuvant therapy for NSCLC patients. CLINICAL TRIAL REGISTRATION:NCT05457049 (CTONG 2201).

Wenhua Liang, Kaican Cai, Qingdong Cao, Chun Chen, Haiquan Chen, Jun Chen, Ke-Neng Chen, Qixun Chen, Tianqing Chu, Yuchao Dong, Jiang Fan, Wentao Fang, Junke Fu, Xiangning Fu, Shugeng Gao, Di Ge, Guojun Geng, Qing Geng, Jie He, Jian Hu, Jie Hu, Wei-Dong Hu, Feng Jiang, Tao Jiang, Wenjie Jiao, He-Cheng Li, Qiang Li, Shanqing Li, Shuben Li, Xiangnan Li, Yong-De Liao, Changhong Liu, Hongxu Liu, Yang Liu, Zhuming Lu, Qingquan Luo, Haitao Ma, Xiaojie Pan, Guibin Qiao, Shengxiang Ren, Weiyu Shen, Yong Song, Daqiang Sun, Guangsuo Wang, Jie Wang, Mengzhao Wang, Qiwen Wang, Wen-Xiang Wang, Li Wei, Ming Wu, Nan Wu, Hui Xia, Shi-Dong Xu, Fan Yang, Kang Yang, Yue Yang, Fenglei Yu, Zhen-Tao Yu, Dong-Sheng Yue, Lanjun Zhang, Weidong Zhang, Zhenfa Zhang, Guofang Zhao, Jian Zhao, Xiaojing Zhao, Chengzhi Zhou, Qinghua Zhou, Kunshou Zhu, Yuming Zhu, Toyoaki Hida, Wolfram C. M. Dempke, Antonio Rossi, Marc de Perrot, Robert A. Ramirez, Mariano Provencio, Jay M. Lee, Antonio Passaro, Lorenzo Spaggiari, Jonathan Spicer, Nicolas Girard, Patrick M. Forde, Tony S. K. Mok, Tina Cascone, Jianxing He; on behalf of CATO consensus group

Abstract Background Lung cancers arising in never smokers have been suggested to be substantially different from lung cancers in smokers at an epidemiological, genetic and molecular level. Focusing on non-small cell lung cancer (NSCLC), we characterized lung cancer patients in China looking for demographic and clinical differences between the smoking and never-smoking subgroups. Methods In total, 891 patients with NSCLC, including 841 with adenocarcinoma and 50 with squamous cell carcinoma, were recruited in this study. Association of smoking status with demographic and clinical features of NSCLC was determined, and risk factors for lymph node metastasis and TNM stage were evaluated using Multivariate logistic regression analysis. Results In patients with adenocarcinoma, never smokers showed a younger age at diagnosis (54.2 ± 12.7vs. 59.3 ± 9.4, p adjusted <0.001), a lower risk for lymph node metastasis than smokers (7,6% vs. 19.5%, p adjusted <0.001) and less severe disease as indicated by lower percentages of patients with TNM stage of III or IV (5.5% vs. 14.7%, p adjusted <0.001 ). By contrast, these associations were not observed in 50 patients with squamous cell carcinoma. Multivariate logistic regression analysis showed that smoking status was a risk factor for lymph node metastasis (OR = 2.70, 95% CI: 1.39–5.31, p = 0.004) but not for TNM stage (OR = 1.18, 95% CI: 0.09–14.43, p = 0.896) in adenocarcinoma. Conclusion This study demonstrates that lung adenocarcinoma in never smokers significantly differ from those in smokers regarding both age at diagnosis and risk of lymph node metastasis, supporting the notion that they are distinct entries with different etiology and pathogenesis.

目的 分析肺结节结构化电子病历是否有助于住院医师规范化培训学员(住培学员)掌握肺结节患者的门诊和住院管理能力.方法 本研究纳入2018年1月-2021年1月在厦门大学附属第一医院外科住院医生规范化培训基地接受培训的120名学员,其中男94人、女26人,年龄22～31(26.45±2.81)岁.随机分为两组,分别使用我科设计的肺结节结构化电子病历(结构化组)和外科通用非结构化电子病历(非结构化组),分析比较两组学员在住院病历撰写时间、首次病程记录完成时间、病程记录的病历质量、开具入院医嘱的准确率、进行教学查房的质量、患者满意度等方面的差异.结果 (1)结构化组住培学员住院病历撰写时间显著短于非结构化组[(53.61±8.12)min vs.(84.25±16.09)min,P＜0.010];同样,结构化组首次病程记录完成时间短于非结构化组,且差异有统计学意义[(13.20±5.43)min vs.(27.51±8.62)min,P＜0.010].(2)结构化组学员教学查房质量评分总体显著高于非结构化组,且差异有统计学意义[(84.21±15.61)分vs.(70.91±12.28)分,P＜0.010].(3)结构化组学员病历书写质量评分显著高于非结构化组,且差异有统计学意义[(80.25±9.22)分vs.(74.22±5.40)分,P＜0.010].结论 肺结节结构化电子病历在外科住院医师规范化培训中能有效提高培训效果,提高学员处理肺结节的临床业务能力,提高学员采集关键临床数据的完整性和准确性,改善医患关系.

非小细胞肺癌是全球癌症死亡的主要原因,其发病率逐年升高,严重危害人类健康.早期的非小细胞肺癌依据症状体征一般难以被发现,因此准确的病理学诊断、精准的预后预测对于非小细胞肺癌患者制定最佳治疗计划、改善患者生存期至关重要.人工智能在非小细胞肺癌诊疗中的应用已显示出良好的性能和巨大的潜力,本文介绍了人工智能在预测非小细胞肺癌分型、分期、基因组学和预后方面的研究进展.

目的:研究Ⅰ、Ⅱ期非小细胞肺癌患者胸腔镜术后并发症发生的影响因素.方法:选取2017年3月-2018年9月厦门大学附属第一医院进行Ⅰ、Ⅱ期非小细胞肺癌治疗患者195例进行临床研究.所有患者均给予VATS肺叶切除术+系统淋巴结清扫术.按照术后患者是否出现并发症将患者分为并发症组和无并发症组.观察两组一般情况、病理情况、围手术期情况.统计分组情况,比较两组一般情况、病理情况、围手术期情况.对Ⅰ、Ⅱ期非小细胞肺癌患者胸腔镜术后并发症发生进行Logistic多因素回归分析.结果:195例患者中有42例出现术后并发症(并发症组),发生率为21.54％,153例未出现术后并发症(无并发症组).并发症组年龄≥60岁、有吸烟史、合并COPD、冠心病占比均高于无并发症组(P<0.05).并发症组Ⅱ期占比高于无并发症组(P<0.05).并发症组手术时间长于无并发症组,术中失血量、术后第1天引流量均多于无并发症组,术后抗生素使用时间长于无并发症组(P<0.05).Logistic结果提示有吸烟史、合并COPD、冠心病、病理分期、手术时间、术后第1天引流量均是Ⅰ、Ⅱ期非小细胞癌患者胸腔镜术后并发症发生的危险因素(P<0.05).结论:对于有吸烟史、合并COPD、冠心病、分期为Ⅱ期、手术时间长、术后第1天引流量大的Ⅰ、Ⅱ期非小细胞癌患者,应注意胸腔镜术后并发症发生的风险.

目的:评价肺磨玻璃结节患者行胸腔镜局限性肺切除术中支气管封堵器(bron-chial blocker,BB)肺隔离的可行性和安全性.方法:选取厦门大学附属第一医院2018年1月-2019年12月拟行胸腔镜下局限性肺切除术肺磨玻璃结节患者122例作为研究对象.采用数字表随机法分为双腔支气管导管(double lumen tube,DLT)组和BB组,各61例.DLT组采用DLT辅助单肺通气行胸腔镜局限性肺切除术,BB组采用BB辅助单肺通气行胸腔镜局限性肺切除术.比较两组患者支气管镜定位用时、手术时长、一次插管成功率、肺萎缩质量、术后咽痛发生率,单肺通气前,单肺通气10、30 min的动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、气道峰压、平均动脉压(MAP).结果:BB组支气管镜定位用时长于DLT组,差异有统计学意义(P<0.05).两组手术时间比较差异无统计学意义(P>0.05).BB组一次性插管成功率为83.61％,高于DLT组的55.74％,BB组术后咽痛发生率为14.75％,明显低于DLT组的45.90％,差异均有统计学意义(P<0.05).两组肺萎缩质量比较差异无统计学意义(P>0.05).两组单肺通气10、30 min的PaO2均低于单肺通气前,气道峰压均高于单肺通气前,差异有统计学意义(P<0.05).两组单肺通气10、30 min的PaCO2、MAP与单肺通气前比较差异均无统计学意义(P>0.05).BB组单肺通气10、30 min的PaO2均高于DLT组,气道峰压均低于DLT组,差异有统计学意义(P<0.05).两组单肺通气10、30 min的PaCO2、MAP比较差异均无统计学意义(P>0.05).结论:肺磨玻璃结节胸腔镜下局限性肺切除术中应用支气管封堵器一次性插管成功率高,是安全可行的肺隔离、单肺通气方法,建议推广应用.